Official Title
Daratumumab Subcutaneous Pre-approval Access Study
Brief Summary
The purpose of this pre-approval access (PAA) program is to provide treatment to participants with serious/life-threatening diseases or conditions.
Approved for marketing
Individual Patients
Drug: Daratumumab
Daratumumab 1800 milligram (mg) will be administered as a fixed dose by subcutaneous (SC) injection.
Eligibility Criteria
Inclusion Criteria:
-
Exclusion Criteria:
-
Eligibility Gender
All
Eligibility Age
Minimum: N/A ~ Maximum: N/A
Janssen Research & Development, LLC Clinical Trial, Study Director
Janssen Research & Development, LLC
Janssen Research & Development, LLC
NCT Number
MeSH Terms
Daratumumab